OrbiMed Capital GP VII LLC
CIK 1760648 · last filed 2025-12-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$226.48M
Companies
11
Total Filings
31
Lifetime Open-Market Net
$225.95M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KROS | Director | 45,057 | $10.15 | $457.3K | $18.01M | 2 | 2025-12-18 |
| PASG | 10%+ Owner | 6,279,600 | $5.81 | $36.48M | $17.76M | 13 | 2025-06-26 |
| MBX | Director | 3,205,930 | $35.51 | $113.84M | $6.06M | 1 | 2025-02-19 |
| Theseus Pharmaceuticals, Inc. (THRX) Delisted | Director | 0 | $4.06 | $0 | $7.74M | 3 | 2024-02-14 |
| Damora Therapeutics, Inc. (GLTO) Delisted | Director | 914,267 | $28.69 | $26.23M | $52.66M | 2 | 2023-07-17 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | 794,368 | $2.65 | $2.11M | $70.72M | 2 | 2023-05-02 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | 762,400 | $52.95 | $40.37M | $5.00M | 1 | 2022-12-28 |
| Sierra Oncology, Inc. (SRRA) Delisted | Director | 226,704 | $54.99 | $12.47M | $0 | 1 | 2022-01-28 |
| JANX | Director | 2,403,566 | $13.56 | $32.59M | -$22.50M | 1 | 2021-12-17 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 97,293 | $2.65 | $257.8K | $40.50M | 3 | 2021-09-02 |
| IMRA | Director | 2,532,402 | $17.02 | $43.10M | $30.00M | 1 | 2021-07-16 |
Recent Filings · Page 2 of 4
31 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-09-23 | PASG | Sell (S) | −78,600 | -$55.8K | EDGAR |
| 2024-09-18 | PASG | Sell (S) | −400,262 | -$293.5K | EDGAR |
| 2024-02-14 | Theseus Pharmaceuticals, Inc. (THRX) Delisted | U | −53,140,800 | $0 | EDGAR |
| 2023-07-17 | Damora Therapeutics, Inc. (GLTO) Delisted | Sell (S) | −973,500 | -$2.34M | EDGAR |
| 2023-05-02 | Kinnate Biopharma Inc. (KNTE) Delisted | Buy (P) | +9,836,176 | $25.72M | EDGAR |
| 2022-12-28 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Buy (P) | +689,655 | $5.00M | EDGAR |
| 2022-11-09 | Theseus Pharmaceuticals, Inc. (THRX) Delisted | Buy (P) | +576,000 | $3.00M | EDGAR |
| 2022-05-05 | PASG | Buy (P) | +101,600 | $508.0K | EDGAR |
| 2022-01-28 | Sierra Oncology, Inc. (SRRA) Delisted | Exer (X) | +1,949,800 | $25.74M | EDGAR |
| 2022-01-24 | PASG | Buy (P) | +738,200 | $4.00M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.